There’s no denying it—the world has changed over the last 18 months. For pharmaceutical companies, acceleration is the new normal. Companies are challenged to push discovery and development timelines to the limit while still adhering to GxP and other regulations and while retaining tight control on intellectual property.
Pharma companies are accelerating the lifecycle of therapeutic development and delivery while trying to squeeze every ounce of optimization out of the process. From leveraging artificial intelligence and high-performance computing in secondary analysis to automating quality assurance and distribution, pharma companies are innovating and transforming their operations to be faster.
But the challenges to accelerate and transform are steep. Competition is fierce. Saving days on the formulation of a therapeutic can mean millions of dollars in revenue. Internal teams and external cooperative organizations are globally distributed in every part of the lifecycle, and cooperation with other biotech and medical firms as well as supply chain organizations is essential. To maintain this open and flexible environment, data can no longer be siloed. Efforts have been made to build data warehouses and lakes, but this takes time. With requirements for data changing at break-neck pace, legacy on-premises technology cannot keep up.
Chief Data Officer - Global Healthcare and Life Sciences at NetApp